Subscribe to RSS
DOI: 10.1055/s-2000-9405
Evidence-Based Outcomes for Patients with Advanced Non-Small Cell Lung Cancer
Publication History
Publication Date:
31 December 2000 (online)
![](https://www.thieme-connect.de/media/srccm/200005/lookinside/thumbnails/10.1055-s-2000-9405-1.jpg)
ABSTRACT
A majority of patients diagnosed with non-small cell lung cancer (NSCLC) will have advanced disease at diagnosis. In the past, systemic therapy (chemotherapy) has demonstrated only slight improvement in survival, hence, practitioners were reluctant to refer patients for cytotoxic therapy. In the past few years, newer chemotherapeutic agents, with increased activity against NSCLC, have been shown to significantly improve median and 1-year survival rates and improve quality of life. Although advanced NSCLC is considered incurable disease, it is, however, potentially treatable disease. This chapter will address the evidence regarding currently available therapies for patients with advanced stage NSCLC.
KEYWORD
Non-small cell lung cancer - advanced stage - chemotherapy
REFERENCES
- 1 Perez E A. Perceptions of prognosis, treatment, and treatment impact on prognosis in non-small cell lung cancer. Chest . 1998; 114 593-604
- 2 Cancer Statistics. CA Cancer J Clin . 1999; 49 8-31
- 3 Cartei G, Cartei F, Cantone A. Cisplatin-cyclophosphamide-mitomycin combination chemotherapy with supportive care versus supportive care alone for treatment of metastatic non-small-cell lung cancer. J Natl Cancer Inst . 1993; 85 794-800
- 4 Cellerino R, Tummarello D, Guidi F. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer. J Clin Oncol . 1991; 9 1453-1461
- 5 Cormier Y, Bergeron D, La Forge J. Benefits of polychemotherapy in advanced non-small-cell bronchogenic carcinoma. Cancer . 1982; 50 845-849
- 6 Ganz P A, Figlin R A, Haskell C M, La Soto N, Siau J. Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference?. Cancer . 1989; 63 1271-1278
- 7 Helsing M, Bergman B, Thaning L. Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised Phase III trial. Joint Lung Cancer Study Group. Eur J Cancer . 1998; 34 1036-1044
- 8 Kaasa S, Lund E, Thorud E. Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer. Cancer . 1991; 67 2443-2447
- 9 Quoix E, Dietemann A, Charbonneau J. [Is chemotherapy with cisplatin useful in non small cell bronchial cancer at staging IV?. <~>Results of a randomized study]. Bull du Cancer . 1991; 78 341-346
- 10 Rapp E, Pater J L, Willan A. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a Canadian multicenter randomized trial. J Clin Oncol . 1988; 6 633-641
- 11 Thongprasert S, Sanguanmitra P, Juthapan W. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: Best supportive care (BSC) versus BSC plus chemotherapy [In Process Citation]. Lung Cancer . 1999; 24 17-24
- 12 Woods R L, Williams C J, Levi J. A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer . 1990; 61 608-611
- 13 O'Connell J P, Kris M G, Gralla R J. Frquency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol . 1986; 4 1604-1614
- 14 Albain K S, Crowley J J, LeBlanc M. Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol . 1991; 9 1618-1626
- 15 Ruckdeschel J C, Finkelstein D M, Mason B A. Chemotherapy for metastatic non-small-cell bronchogenic carcinoma: EST 2575, generation V-a randomized comparison of four cisplatin-containing regimens. J Clin Oncol . 1985; 3 72-79
- 16 Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ . 1995; 311 899-909
- 17 Marino P, Pampallona S, Preatoni A. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest . 1994; 106 861-865
- 18 Souquet P J, Chauvin F, Boissel J P. Meta-analysis of randomised trials of systemic chemotherapy versus supportive treatment in non-resectable non-small cell lung cancer. Lung Cancer . 1995; 12 S147-S154
- 19 Grilli R, Oxman A D, Julian J A. Chemotherapy for advanced non-small-cell lung cancer: How much benefit is enough?. J Clin Oncol . 1993; 11 1866-1872
- 20 Le Chevalier T, Brisgand D, Douillard J Y. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol . 1994; 12 360-367
- 21 Cardenal F, Lopez-Cabrerizo M P, Anton A. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metaststic non-small-cell lung cancer. J Clin Oncol . 1999; 17 12-18
- 22 Giaccone G, Postmus P, Debruyne C. Final results of an EORTC phase III study of paclitaxel versus teniposide, in combination with cisplatin, in advanced NSCLC. Proc Am Soc Clin Oncol . 1997; 16(abstract 1653) 460a
- 23 Belani C P, Natale R B, Lee J S, Socinski M. Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung (NSCLC). Proc Am Soc Clin Oncol . 1998; 17(abstract 1751) 455a
- 24 Bonomi P, Kim K, Chang A. Phase III trial comparing etoposide (E), cisplatin (C) versus Taxol (T) with cisplatin-G-CSF (G) versus taxol-cisplatin in advanced non-small cell lung cancer. An Eastern Cooperative Group (ECOG) trial. Proc Am Soc Clin Onc . 1996; 15(abstr) 382
- 25 Gatzmeier U, von Pawel J, Gottfried M. Phase III comparative study of high-dose cisplatin (HD-CIS) versus a combination of paclitaxel (TAX) and cisplatin (CIS) in patients with advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol . 1998; 17(abstract 1748) 454a
- 26 Kelly K, Crowley J, Bunn P A. A Randomized Phase III Trial of Paclitaxel Plus Carboplatin (PC) Versus Vinorelbine Plus Cisplatin (VC) in Untreated Advanced Non-Small Cell Lung Cancer (NSCLC): A Southwest Oncology Group (SWOG) Trial. Proc Am Soc Clin Onc . 1999; (abstract 1777) 18a
- 27 Sandler A, Nemunaitis J, Dehnam C. Phase III study of cisplatin (C) with or without gemcitabine (G) in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol . 1998; 17(abstract 1747) 454a
- 28 Wozniak A J, Crowley J J, Balcerzak S P. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study. J Clin Oncol . 1998; 16 2459-2465
- 29 Comella P, Frasci G, Panza N. Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: A Phase II randomized study of the Southern Italy Cooperative Oncology Group. J Clin Oncol . 1999; 17 1526-1534
- 30 Comella P, Panz N, Nicolella G. Cisplatin-gemcitabine-vinorelbine vs cisplatin-vinorelbine in advanced non-small-cell lung cancer: Interim analysis of a SICOG phase III trial. Eur J Cancer. 1999; 35(suppl 4)(abstract #977) 247
- 31 Inoperable non-small-cell lung cancer (NSCLC): A Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Report to the Medical Research Council by its Lung Cancer Working Party. Br J Cancer . 1991; 63 265-270
- 32 Donato V, Zurlo A, Bonfili P. Hypofractionated radiation therapy for inoperable advanced stage non-small cell lung cancer. Tumori . 1999; 85 174-176
- 33 Curran Jr W. New therapeutic strategies involving radiation therapy for patients with non-small cell lung cancer. Chest . 1995; 302S-305S (302S-305S)
- 34 Fernandez C, Rosell R, Abad-Esteve A. Quality of life during chemotherapy in non-small cell lung cancer patients. Acta Oncol . 1989; 28 29-33
- 35 Ellis P A, Smith I E, Hardy J R. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer . 1995; 71 366-370
- 36 Jakkimainen L, Goodwin P J, Pater J. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. J Clin Oncol . 1990; 8 1301-1309
- 37 Smith T J, Hillner B E, Neighbors D M. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer. J Clin Oncol . 1995; 13 2166-2173
- 38 Earle C C, Evans W K. A comparison of the costs of paclitaxel and best supportive care in stage IV non-small-cell lung cancer. Cancer Prev Control . 1997; 1 282-288
- 39 Evans W K, Le Chevalier T. The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer. Eur J Cancer . 1996; 32A 2249-2255